

IN THE UNITED STATES PATENT AND TRADEMARK OF

In re Application of:

Norman NASHED et al.

Serial No.: 09/619,493

RECEIVED

MAY 2 2 2003

CHOCENTER 1600/2900 Group Art Unit: 1616

Filed: July 19, 2000

Examiner: S.N. Qazi

For: THERAPEUTIC GESTAGENS FOR THE TREATMENT OF PREMENSTRUAL

DYSPHORIC DISORDER

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 RECEIVED OCT 1 5 2003

Sir:

TECH CENTER 1600/2900

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

		nder 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information sclosure statement is filed:					
			three months of the filing date of a national application other than a CPA § 1.53(d);				
			three months of the actual filing date of the national phase of a PCT ation; OR				
		before RCE).	the mailing of a first substantive office action (including after filing of an				
\boxtimes	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of:						
		\boxtimes	a final rejection under 37 C.F.R. 1.113;				
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR				
			a notice of allowance under 37 C.F.R. § 1.311; and				
RDOFi	00000040	09519493					

05/21/2003 GUO:

02 70:1806

180.00 OP

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known Application Number 09/619,493 INFORMATION DISCLOSURE Filing Date July 19, 2000 STATEMENT BY APPLICANT N. NASHED et al. First Named Inventor 1616 Group Art Unit (use as many sheets as necessary) **Examiner Name** S.N. Qazi SCH 1686 C1 Sheet Attorney Docket Number of

			U.S. PAT	TENT DOCUMENTS	
Examiner	Cite No.1	U.S. Patent Do	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Nambor	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
					
	·				
					RECEIME
					OCT 1 5 2003
					TECH CENTER 1600/2
					· · · · · · · · · · · · · · · · · · ·

	FOREIGN PATENT DOCUMENTS								
		F	oreign Patent Doc	ument		Date of Publication of	Pages, Columns, Lines, Where Relevant		
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T [€]	
								•	

	A part of the second se	
Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PADEMARY PI Please type a plus sign (+) inside this box

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO					Complete if Known					
		388 TIAL	DIOO		Application Number	09/619,493	RECE	MED		
		RMATION			Filing Date	July 19, 2000				
	STAT	EMENT B	Y APP	PLICANT	First Named Inventor	N. NASHED et				
					Group Art Unit	1616	00113	2003		
	(use as many sh	eets as ne	cessary)	Examiner Name	S.N. Qazi	TEOURS			
	Sheet	2	of	2	Attorney Docket Number	SCH 1686 C1	TECH CENTER	¹ 600/2900		
_								' ''''/ <i>EYUU</i>		

		NON PATENT LITERATURE DOCUMENTS	+ 1
xaminer Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т,
Ü	B1	E. Freeman et al., Evaluation of a Unique Oral Contraceptive in the Treatment of Premenstrual Dysphoric Disorder, Journal of Women's Heath & Gender-Based Medicine, Vol. 10, No. 6, 2001, pp. 561-569	
		E. Freeman et al., A Double-blind Trial of Oral Progesterone, Alprazolam, and Placebo in Treatment of Severe Premenstrual Syndrome, JAMA, Vol. 274, No. 1, July 5, 1995, pp. 51-57	
	В3	P.M. 'Brien et al., <i>Treatment of Premenstrual Syndrome by Spironolactone</i> , British Journal of Obstetrics and Gynaecology, Vol. 86, February 1979, pp. 142-147	
		D. Hellberg et al., Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate, Int. J. Gynecol. Obstet., 1991; 34: pp. 243-248	
	B5	M. Wang et al., Treatment of premenstrual syndrome by spironolactone: A double-blind, placebo-controlled study, Acta Obstet Gynecol Scand. 1995: 74: pp. 803-808	
	В6	R.B. Burnet et al., <i>Premenstrual Syndrome and Spironolactone</i> , Aust NZ J. Obstet Gynaecol 1991; 31: 4: 366	
		K. Aslasksen et al., Spironolactone in the Treatment of Premenstrual Tension: A Double- Blind Study of Spironolactone Versus Bendroflumethiazide and Placebo, Current Therapeutic Research, Vol. 49, No. 1, January 1991, pp. 120-130	

	The state of the s		
Examiner		Date	
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.